ArticleAntibiotics (Basel, Switzerland)2026
Etiological and Epidemiological Characteristics of Severe Mastitis and the Outcomes Treatment Following a Single Dose of Fluoroquinolones Administered During On-Farm Veterinary Interventions.
Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivessevere mastitis is one of the leading causes of mortality in dairy cows. Its primary complication is shock, predominantly associated with systemic inflammatory response syndrome, which remains extremely challenging for practitioners to manage. The average mortality rate is estimated at approximately 25%. Many authors recommend the use of fluoroquinolones for this indication. However, these antibiotics are classified as critically important for human health, and their use requires strict compliance with specific guidelines (bacteriological analysis and antimicrobial susceptibility testing). In addition, some practitioners remain reluctant to use this class of antibiotics in field conditions. Therefore, the present study aimed to evaluate the outcomes of systematic antibiotic therapy using fluoroquinolones in cases of severe mastitis and to identify factors that may influence treatment success.
methodsa total of 323 cows with severe mastitis were enrolled by eight participating veterinary clinics located across different regions of France. The study design included: (i) clinical scoring based on a standardized grid developed by practitioners routinely managing this condition, (ii) bacteriological analysis of milk samples (with antimicrobial susceptibility testing performed when Gram-negative bacteria were isolated), and (iii) post-treatment follow-up consisting of telephone interviews conducted at 5 and 15 days after inclusion. Cows presenting with a clinical score ≥3 (scale 0-36) in association with local signs of mastitis were classified as having severe mastitis and received an injection of 10 mg/kg marbofloxacin along with 2.2 mg/kg flunixin (unless another NSAID had been administered within the previous 24 h). When the clinical score was ≥6, cows additionally received intravenous fluid therapy consisting of 3 L of 7.2% NaCl, supplemented by oral drenching if spontaneous water intake was insufficient.
resultsa total of 43 cows died or were euthanized during the study period, corresponding to a mortality rate of 13.3%. The mean clinical score at inclusion was 12.6. The clinical signs most strongly associated with mortality were decubitus and hypothermia at admission.
conclusionthe timeliness of initiating effective antimicrobial therapy appears to be a critical determinant of survival in cows with severe mastitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.